Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
|Articles|April 19, 2022
Daily Medication Pearl: Paliperidone Palmitate (Invega Hafyera)
Author(s)Saro Arakelians, PharmD
Invega Hafyera is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.
Advertisement
Medication Pearl of the Day: Paliperidone Palmitate (Invega Hafyera)
Indication: Invega Hafyera, an every 6-month injection, is an atypical antipsychotic indicated for the treatment of schizophrenia in adults. Before transitioning to Invega Hafyera, patients must have been adequately treated with Invega Sustenna (1-month paliperidone palmitate) for at least 4 months or Invega Trinza (3-month paliperidone palmitate) for at least one 3-month injection cycle.
Insight:
- Dosing: Dosing can vary and can be 1092 mg or 1560 mg—see package insert.
- Dosage forms: Extended-release injectable suspension 1092 mg/3.5 mL or 1560 mg/5 mL single-dose prefilled syringes.
- Adverse events: The most common adverse reactions were upper respiratory tract infection, injection site reaction, weight increase, headache, and parkinsonism.
- Mechanism of action: Paliperidone palmitate is hydrolyzed to paliperidone. Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, its efficacy in the treatment of schizophrenia could be mediated through a combination of central dopamine D2 and serotonin 5HT2A receptor antagonism
- Manufacturer: Janssen Pharmaceuticals
Source:
Advertisement
Related to this article
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
3
Preparing Pharmacists for Psychedelic Medicine
4
Could Cemdisiran Keep Patients With Myasthenia Gravis Out of the Hospital?
5